OPKO Health, Inc. (0KCS.L)
USD 1.42
(0.71%)
USD 1.42
(0.71%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 574.68 Million USD | -26.99% |
| 2022 | 534.4 Million USD | -10.34% |
| 2021 | 596 Million USD | 22.31% |
| 2020 | 487.3 Million USD | -7.36% |
| 2019 | 526 Million USD | -4.69% |
| 2018 | 551.9 Million USD | -11.8% |
| 2017 | 625.74 Million USD | -6.12% |
| 2016 | 666.5 Million USD | 90.47% |
| 2015 | 349.93 Million USD | 129.57% |
| 2014 | 152.43 Million USD | 26.65% |
| 2013 | 120.35 Million USD | 116.27% |
| 2012 | 55.65 Million USD | 64.04% |
| 2011 | 33.92 Million USD | 29.81% |
| 2010 | 26.13 Million USD | -11.71% |
| 2009 | 29.6 Million USD | -22.2% |
| 2008 | 38.04 Million USD | 57.63% |
| 2007 | 24.13 Million USD | 2060.88% |
| 2006 | 1.11 Million USD | -22.32% |
| 2005 | 1.43 Million USD | -29.89% |
| 2004 | 2.05 Million USD | -45.23% |
| 2003 | 3.74 Million USD | -60.92% |
| 2002 | 9.58 Million USD | -19.15% |
| 2001 | 11.85 Million USD | 21.44% |
| 2000 | 9.75 Million USD | 70.43% |
| 1999 | 5.72 Million USD | 33.16% |
| 1998 | 4.3 Million USD | 22.86% |
| 1997 | 3.5 Million USD | 9.38% |
| 1996 | 3.2 Million USD | 77.78% |
| 1995 | 1.8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 92.1 Million USD | -0.21% |
| 2024 Q2 | 92.9 Million USD | 0.87% |
| 2023 Q1 | 129.8 Million USD | 12.77% |
| 2023 Q2 | 119.48 Million USD | -7.94% |
| 2023 Q3 | 113.2 Million USD | -5.26% |
| 2023 FY | 390.15 Million USD | -26.99% |
| 2023 Q4 | 92.3 Million USD | -18.46% |
| 2022 Q2 | 141.51 Million USD | -10.36% |
| 2022 Q1 | 157.87 Million USD | -8.05% |
| 2022 FY | 534.4 Million USD | -10.34% |
| 2022 Q3 | 119.87 Million USD | -15.29% |
| 2022 Q4 | 115.1 Million USD | -3.98% |
| 2021 FY | 596 Million USD | 22.31% |
| 2021 Q1 | 144.17 Million USD | 9.31% |
| 2021 Q4 | 171.7 Million USD | 26.22% |
| 2021 Q3 | 136.03 Million USD | -5.55% |
| 2021 Q2 | 144.03 Million USD | -0.1% |
| 2020 Q4 | 131.9 Million USD | -0.28% |
| 2020 Q1 | 112.83 Million USD | -3.97% |
| 2020 Q3 | 132.26 Million USD | 19.95% |
| 2020 FY | 487.3 Million USD | -7.36% |
| 2020 Q2 | 110.26 Million USD | -2.27% |
| 2019 Q4 | 117.5 Million USD | -7.46% |
| 2019 Q1 | 148.3 Million USD | 2.35% |
| 2019 Q2 | 133.18 Million USD | -10.2% |
| 2019 Q3 | 126.97 Million USD | -4.66% |
| 2019 FY | 526 Million USD | -4.69% |
| 2018 Q3 | 131.13 Million USD | -2.21% |
| 2018 Q4 | 144.9 Million USD | 10.5% |
| 2018 Q1 | 141.7 Million USD | -25.26% |
| 2018 FY | 551.9 Million USD | -11.8% |
| 2018 Q2 | 134.09 Million USD | -5.37% |
| 2017 Q4 | 189.6 Million USD | 4.35% |
| 2017 Q3 | 181.68 Million USD | 1.57% |
| 2017 Q1 | 180.63 Million USD | 9.34% |
| 2017 Q2 | 178.88 Million USD | -0.97% |
| 2017 FY | 625.74 Million USD | -6.12% |
| 2016 FY | 666.5 Million USD | 90.47% |
| 2016 Q4 | 165.2 Million USD | -1.31% |
| 2016 Q3 | 167.4 Million USD | 1.68% |
| 2016 Q2 | 164.63 Million USD | -2.73% |
| 2016 Q1 | 169.26 Million USD | 18.87% |
| 2015 Q4 | 142.39 Million USD | 73.03% |
| 2015 Q1 | 71.5 Million USD | 63.68% |
| 2015 Q2 | 53.74 Million USD | -24.84% |
| 2015 Q3 | 82.29 Million USD | 53.12% |
| 2015 FY | 349.93 Million USD | 129.57% |
| 2014 Q4 | 43.68 Million USD | 17.24% |
| 2014 Q2 | 33.93 Million USD | -9.63% |
| 2014 FY | 152.43 Million USD | 26.65% |
| 2014 Q1 | 37.55 Million USD | -10.03% |
| 2014 Q3 | 37.26 Million USD | 9.81% |
| 2013 Q2 | 26.12 Million USD | 4.3% |
| 2013 FY | 120.35 Million USD | 116.27% |
| 2013 Q4 | 41.73 Million USD | 52.06% |
| 2013 Q3 | 27.44 Million USD | 5.06% |
| 2013 Q1 | 25.04 Million USD | 31.81% |
| 2012 Q3 | 13.12 Million USD | 9.04% |
| 2012 Q2 | 12.03 Million USD | -4.78% |
| 2012 Q4 | 19 Million USD | 44.83% |
| 2012 Q1 | 12.63 Million USD | 24.98% |
| 2012 FY | 55.65 Million USD | 64.04% |
| 2011 Q3 | 8.59 Million USD | -5.49% |
| 2011 FY | 33.92 Million USD | 29.81% |
| 2011 Q4 | 10.11 Million USD | 17.65% |
| 2011 Q2 | 9.09 Million USD | 12.11% |
| 2011 Q1 | 8.11 Million USD | -18.3% |
| 2010 FY | 26.13 Million USD | -11.71% |
| 2010 Q2 | 8.13 Million USD | 25.88% |
| 2010 Q4 | 9.92 Million USD | 9.24% |
| 2010 Q1 | 6.46 Million USD | -20.72% |
| 2010 Q3 | 9.08 Million USD | 11.76% |
| 2009 Q2 | 5.83 Million USD | -37.46% |
| 2009 Q1 | 9.32 Million USD | -4.22% |
| 2009 FY | 29.6 Million USD | -22.2% |
| 2009 Q4 | 8.14 Million USD | 29.33% |
| 2009 Q3 | 6.3 Million USD | 8.06% |
| 2008 Q4 | 9.73 Million USD | 7.4% |
| 2008 FY | 38.04 Million USD | 57.63% |
| 2008 Q1 | 10.12 Million USD | 11.25% |
| 2008 Q2 | 9.12 Million USD | -9.89% |
| 2008 Q3 | 9.06 Million USD | -0.69% |
| 2007 Q1 | -243.74 Million USD | -51200.42% |
| 2007 Q4 | 9.1 Million USD | 588.04% |
| 2007 Q3 | -1.86 Million USD | -117.31% |
| 2007 Q2 | 10.77 Million USD | 104.42% |
| 2007 FY | 24.13 Million USD | 2060.88% |
| 2006 Q2 | 170 Thousand USD | -9.57% |
| 2006 Q3 | 280 Thousand USD | 64.71% |
| 2006 Q4 | 477 Thousand USD | 70.36% |
| 2006 FY | 1.11 Million USD | -22.32% |
| 2006 Q1 | 188 Thousand USD | -56.28% |
| 2005 Q2 | 484 Thousand USD | 46.22% |
| 2005 FY | 1.43 Million USD | -29.89% |
| 2005 Q4 | 430 Thousand USD | 121.65% |
| 2005 Q3 | 194 Thousand USD | -59.92% |
| 2005 Q1 | 331 Thousand USD | 2.48% |
| 2004 Q4 | 323 Thousand USD | -19.05% |
| 2004 FY | 2.05 Million USD | -45.23% |
| 2004 Q2 | 560 Thousand USD | -27.18% |
| 2004 Q3 | 399 Thousand USD | -28.75% |
| 2004 Q1 | 769 Thousand USD | 205.49% |
| 2003 Q2 | 1.84 Million USD | 71.53% |
| 2003 Q1 | 1.07 Million USD | -50.09% |
| 2003 Q3 | 1.55 Million USD | -15.67% |
| 2003 FY | 3.74 Million USD | -60.92% |
| 2003 Q4 | -729 Thousand USD | -146.88% |
| 2002 Q1 | 2.3 Million USD | -14.58% |
| 2002 Q2 | 2.28 Million USD | -0.78% |
| 2002 FY | 9.58 Million USD | -19.15% |
| 2002 Q3 | 2.84 Million USD | 24.39% |
| 2002 Q4 | 2.15 Million USD | -24.18% |
| 2001 Q3 | 3.37 Million USD | -7.54% |
| 2001 Q4 | 2.69 Million USD | -20.12% |
| 2001 FY | 11.85 Million USD | 21.44% |
| 2001 Q1 | 2.13 Million USD | 1.67% |
| 2001 Q2 | 3.64 Million USD | 71.15% |
| 2000 FY | 9.75 Million USD | 70.43% |
| 2000 Q1 | 2.88 Million USD | 57.83% |
| 2000 Q4 | 2.09 Million USD | -21.25% |
| 2000 Q2 | 2.11 Million USD | -26.54% |
| 2000 Q3 | 2.66 Million USD | 25.79% |
| 1999 Q3 | 1.4 Million USD | 16.67% |
| 1999 FY | 5.72 Million USD | 33.16% |
| 1999 Q4 | 1.82 Million USD | 30.43% |
| 1999 Q2 | 1.2 Million USD | -14.29% |
| 1999 Q1 | 1.4 Million USD | 27.27% |
| 1998 Q4 | 1.1 Million USD | -15.38% |
| 1998 FY | 4.3 Million USD | 22.86% |
| 1998 Q1 | 800 Thousand USD | 0.0% |
| 1998 Q2 | 1.1 Million USD | 37.5% |
| 1998 Q3 | 1.3 Million USD | 18.18% |
| 1997 FY | 3.5 Million USD | 9.38% |
| 1997 Q1 | 700 Thousand USD | -12.5% |
| 1997 Q2 | 900 Thousand USD | 28.57% |
| 1997 Q3 | 1 Million USD | 11.11% |
| 1997 Q4 | 800 Thousand USD | -20.0% |
| 1996 FY | 3.2 Million USD | 77.78% |
| 1996 Q1 | 700 Thousand USD | 0.0% |
| 1996 Q2 | 700 Thousand USD | 0.0% |
| 1996 Q3 | 1 Million USD | 42.86% |
| 1996 Q4 | 800 Thousand USD | -20.0% |
| 1995 FY | 1.8 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 94.395% |
| Dynavax Technologies Corporation | 219.14 Million USD | -162.24% |
| Illumina, Inc. | 3.81 Billion USD | 84.928% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 72.008% |
| Biogen Inc. | 5.2 Billion USD | 88.959% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -27.427% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 47.247% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 57.769% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -8.634% |
| Waters Corporation | 943.51 Million USD | 39.091% |
| Perrigo Company plc | 1.52 Billion USD | 62.402% |
| uniQure N.V. | 285.08 Million USD | -101.583% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -40.577% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -34.382% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -108.451% |
| bluebird bio, Inc. | 240.23 Million USD | -139.221% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -303.393% |
| Imunon, Inc. | 21.03 Million USD | -2632.64% |
| Myriad Genetics, Inc. | 600.1 Million USD | 4.235% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 64.003% |
| Nektar Therapeutics | 190.9 Million USD | -201.036% |
| Editas Medicine, Inc. | 247.3 Million USD | -132.38% |
| Verastem, Inc. | 92.08 Million USD | -524.089% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 98.585% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -4031.566% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -376.297% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1186.601% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 67.091% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -151.306% |
| Evolus, Inc. | 189.75 Million USD | -202.85% |
| Adicet Bio, Inc. | 152.03 Million USD | -277.988% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -4633.432% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 79.587% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -111.362% |
| FibroGen, Inc. | 398.11 Million USD | -44.352% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 72.828% |
| Homology Medicines, Inc. | 9.87 Million USD | -5719.605% |
| Geron Corporation | 70.44 Million USD | -715.84% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 68.074% |
| Exelixis, Inc. | 1.58 Billion USD | 63.783% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -469.972% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -930.716% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -4.192% |
| Zoetis Inc. | 2.76 Billion USD | 79.216% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -20.641% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -1084.871% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 87.965% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -1367.796% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 26.283% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -55.905% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -91.998% |
| Blueprint Medicines Corporation | 722.86 Million USD | 20.498% |
| Insmed Incorporated | 949.26 Million USD | 39.46% |
| TG Therapeutics, Inc. | 198.47 Million USD | -189.551% |
| Incyte Corporation | 1.19 Billion USD | 51.727% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 44.953% |